Arvinas Overview

  • Founded
  • 2013
Founded
  • Status
  • Public
  • Employees
  • 133
Employees
  • Stock Symbol
  • ARVN
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $82.51
  • (As of Monday Closing)

Arvinas General Information

Description

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 5 Science Park
  • 395 Winchester Avenue
  • New Haven, CT 06511
  • United States
+1 (203) 000-0000

Arvinas Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Arvinas Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$82.51 $84.09 $19.68 - $92.77 $3.9B 47.3M 1.22M -$2.57

Arvinas Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 688,213 1,415,388 643,278
Revenue 24,477 42,976 14,324 7,579
EBITDA (99,537) (72,511) (43,187) (23,853)
Net Income (98,833) (70,292) (41,480) (24,049)
Total Assets 271,947 301,641 199,282 66,848
Total Debt 4,291 4,388 2,154 310
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Arvinas Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Arvinas‘s full profile, request access.

Request a free trial

Arvinas Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Arvinas‘s full profile, request access.

Request a free trial

Arvinas Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degr
Biotechnology
New Haven, CT
133 As of 2019
00000
000000 - 000 00000

00 00000

rit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidata
0000 000000000
Watertown, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000 0

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000000
Jerusalem, Israel
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arvinas Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
C4 Therapeutics Formerly VC-backed Watertown, MA 00 00000 00000000 00000
000000 0000 Formerly VC-backed Jerusalem, Israel 00 00000 00000000 00000
0000000 Venture Capital-Backed Cambridge, MA 000 00000000000 000
000000000000 00000 Venture Capital-Backed Jerusalem, Israel 00 000.00 000000000000 000.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 26 competitors. Get the full list »

Arvinas Executive Team (15)

Name Title Board Seat Contact Info
John Houston Ph.D Chief Executive Officer & Board Member
Sean Cassidy Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Ian Taylor Ph.D Chief Scientific Officer
Craig Crews Ph.D Founder & Chief Scientific Advisor
Daniel Von Hoff MD Scientific Advisor
You’re viewing 5 of 15 executive team members. Get the full list »

Arvinas Board Members (19)

Name Representing Role Since
Bradley Margus Self Board Member 000 0000
Briggs Morrison MD Self Board Member 000 0000
Edward Kennedy Jr. Self Board Member 000 0000
Jakob Loven Ph.D Self Board Member 000 0000
John Houston Ph.D Arvinas Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Arvinas Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arvinas Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Arvinas‘s full profile, request access.

Request a free trial

Arvinas Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000 15-Jul-2019 00000 0000000 Biotechnology 0000 0000000 00.0
To view Arvinas’s complete investments history, request access »